valsartan has been researched along with Diabetic Nephropathies in 81 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (2.47) | 18.2507 |
| 2000's | 32 (39.51) | 29.6817 |
| 2010's | 33 (40.74) | 24.3611 |
| 2020's | 14 (17.28) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, J; Jiang, D; Sun, F | 1 |
| Jiang, Y; Liu, C; Yu, M | 1 |
| Kozak, PM; Stacey, RB; Upadhya, B; Vasan, RS | 1 |
| Chen, J; Chen, S; Li, G; Qin, S; Qin, Y; Wang, S | 1 |
| Ai, SS; Cui, T; Gao, RR; Han, C; Hu, HZ; Li, W; Liu, Y; Shen, Z; Sui, GY | 1 |
| Su, F; Xia, Q | 1 |
| Handa, T; Ikushima, A; Inoue, Y; Ishii, A; Ishimura, T; Kato, Y; Minamino, N; Mori, KP; Mukoyama, M; Nishio, H; Ohno, S; Sugioka, S; Yamada, H; Yanagita, M; Yokoi, H | 1 |
| Ding, Y; Duan, FY; Huang, SL; Jia, PP; Ren, XQ; Song, CD; Song, D; Wang, YX; Zhai, WS | 1 |
| Hu, L; Liu, G; Wei, Y | 1 |
| Chen, Y; Han, X; Liu, J; Ma, Y; Xie, D; Xu, H | 1 |
| Jiang, Z; Li, X; Meng, F; Tan, Z | 1 |
| Bo, W; Chen, H; Hongbao, L; Li, L; Peng, Z; XiaoWei, L; Xiong, C | 1 |
| Ding, Z; Li, Y; Liu, R; Wang, Q; Zang, Y; Zhang, G; Zhang, X | 1 |
| Chen, H; Liu, F; Ma, Q; Yang, H | 1 |
| Keshawy, MM; Makary, S; Tawfik, MK | 1 |
| Liu, ZY; Shan, C; Wu, H; Yu, J; Zhang, KQ; Zhu, Q | 1 |
| An, S; Duan, L; Gao, Y; Liu, J; Liu, Y; Tian, L; Wang, J; Wang, S; Wei, S; Zhou, S | 1 |
| Ahmad, SNS; Argani, H; Aslani, S; Ghorbani Haghjo, A; Jigheh, ZA; Mesgari Abbasi, M; Panah, F; Rashedi, J; Roshangar, L; Sanajou, D | 1 |
| Aparicio, MC; Aucella, F; Battaglia, G; Belviso, A; Bossi, AC; Carrara, F; Cortinovis, M; David, S; Diadei, O; Gaspari, F; Gregoric, N; Iliev, IP; Janez, A; Manunta, P; Martinetti, D; P Barlovic, D; Parvanova, A; Peraro, F; Perna, A; Pisani, A; Remuzzi, G; Riccio, E; Rota, S; Ruggenenti, P; Ruggiero, B; Satta, A; Stucchi, N; Trevisan, R; Trillini, M | 1 |
| Aroor, AR; Chandrasekar, B; Das, NA; DeMarco, VG; Habibi, J; Hayden, MR; Johnson, MS; Manrique-Acevedo, CM; Nistala, R; Wiedmeyer, C | 1 |
| Abdo, M; Hassan, WA; Makary, S; Tawfik, MK | 1 |
| Ge, Y; Hou, J; Jin, B; Li, S; Liu, Z; Shi, M; Xie, H; Zhang, H | 1 |
| El-Maraghy, SA; Motawi, TK; Senousy, MA | 1 |
| Gnudi, L; Hill, B; Karalliedde, J; Maltese, G; Viberti, G | 1 |
| Cheung, AK; Huang, Y; Liu, X; Zhou, G | 1 |
| Howard, A; Kopp, JB; Levi, M; Li, C; Qiu, L; Solis, N; Wang, W; Wang, X | 1 |
| Guo, T; Hao, P; Kong, J; Li, D; Meng, X; Yang, J; Zhang, C; Zhang, K; Zhang, M; Zhang, Y | 1 |
| Guo, ZA; Li, Y; Liu, G; Meng, FC; Peng, SL; Yu, CJ | 1 |
| Chen, JF; Hung, YJ; Lee, IT; Lee, WJ; Sheu, WH; Wang, CY | 1 |
| Hou, XL; Jin, H; Wu, J; Zhang, B; Zhang, HB; Zhang, HN | 1 |
| Batenburg, WW; Bhaggoe, UM; Clahsen-van Groningen, MC; Danser, AH; de Vries, R; Friesema, EC; Garrelds, IM; Hoorn, EJ; Leijten, FP; Roksnoer, LC; van Gool, JM; van Veghel, R | 1 |
| Peng, W; Qiao, H; Wang, L; Wang, Y; Wu, C; Xu, Z; Zhang, X | 1 |
| Galle, J | 1 |
| Chen, B; Guan, GJ; Hou, XH; Li, XG; Liu, G; Liu, JL; Zhang, Y | 1 |
| Abadir, PM; Abdel-Rahman, EM; Siragy, HM | 1 |
| Hamamoto, Y; Honjo, S; Ikeda, H; Koshiyama, H; Nabe, K; Wada, Y | 1 |
| Chihara, K; Dan, T; Izuhara, Y; Kurokawa, K; Miyata, T; Ohtomo, S; Robert, A; Tominaga, N; Van Ypersele de Strihou, C | 1 |
| Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Lai, ZF; Liu, L; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yamamoto, E | 1 |
| Kamal, F; Morioka, T; Oite, T; Piao, H; Yanakieva-Georgieva, N | 1 |
| Blanco-Colio, LM; Carrero, JJ; Celik, T; Egido, J; Eyileten, T; Martín-Ventura, JL; Moreno, JA; Saglam, M; Sonmez, A; Yaman, H; Yenicesu, M; Yilmaz, MI | 1 |
| Gao, Q; Liu, Z; Qin, W; Shen, W; Wang, J; Wang, S; Zeng, C; Zhang, M; Zheng, C; Zhu, X | 1 |
| Biro, S; Ikeda, Y; Kono, S; Otonari, T; Saikawa, T; Sasaki, J | 1 |
| Aizawa, Y; Suzuki, K | 1 |
| Huang, J; Matavelli, LC; Siragy, HM | 1 |
| Higashi, K; Hiroo, K; Kushiyama, T; Oda, T; Yamamoto, K | 1 |
| Dejima, T; Fujikawa, T; Haku, S; Kanaoka, T; Kondoh, S; Konno, Y; Maeda, A; Mitsuhashi, H; Mizushima, S; Moriya, T; Ogawa, N; Ohsawa, M; Okano, Y; Ozawa, M; Suzuki, D; Tamura, K; Tanaka, K; Toyoda, M; Umemura, S; Umezono, T; Wakui, H; Yamakawa, T; Yanagi, M | 1 |
| Cheng, YN; Gao, JJ; Jiao, B; Wang, YS; Zhang, QZ | 1 |
| Chen, H; Li, H; Liu, Z; Tang, L; Yang, B; Yi, R | 1 |
| Kumagai, H; Matsubara, H; Oda, T; Ohshima, N; Senda, M; Tadano, H; Takechi, H; Uchida, T; Watanabe, A; Yamamoto, K | 1 |
| Imanishi, M; Kitabayashi, C; Konishi, Y; Maeda, I; Masada, M; Morikawa, T; Nishiyama, A; Okada, N; Shirahashi, N; Wilcox, CS | 1 |
| Aritomi, S; Konda, T; Niinuma, K; Nitta, K; Ogawa, T | 1 |
| Bai, WW; Sun, HL; Xiang, GD; Yue, L; Zhao, LS | 1 |
| Aizawa, Y; Ikarashi, T; Kaneko, S; Nakagawa, O; Souda, S; Suzuki, K | 1 |
| Viberti, G; Wheeldon, NM | 1 |
| Allen, TJ; Cao, Z; Cooper, ME; Davis, BJ; de Gasparo, M; Kawachi, H | 1 |
| Andersen, S; Jacobsen, P; Jensen, BR; Parving, HH | 1 |
| Abadir, P; Awad, A; Siragy, HM; Webb, R | 1 |
| Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV | 1 |
| Ivanova, NA; Preobrazhenskiĭ, DV; Sidorenko, BA; Soplevenko, AV; Stetsenko, TM | 1 |
| Suzuki, H | 1 |
| Awad, AS; Carey, RM; Siragy, HM; Webb, RL | 1 |
| Temple, R | 1 |
| Hausberg, M; Hohage, H; Kosch, M | 1 |
| Böger, RH; Maas, R; Quispe-Bravo, S; Schwedhelm, E; Skamira, C | 1 |
| Jacobsen, PK; Parving, HH; Rossing, P | 1 |
| Ito, S; Kato, T; Mori, T; Nako, K; Ogawa, S; Takeuchi, K | 1 |
| Berho, M; Elliot, SJ; Plati, AR; Potier, M; Striker, GE; Striker, LJ; Zeng, YJ; Zheng, F | 1 |
| Coll, JR; Estacio, RO; Schrier, RW; Tran, ZV | 1 |
| Chen, B; Guan, GJ; Hou, XH; Li, XG; Liu, G; Liu, HY; Zhang, Y | 1 |
| Inaba, M; Inukai, K; Izumida, T; Katayama, S; Noguchi, Y; Yagi, S; Yamaguchi, M; Yamamoto, H | 1 |
| Karashima, S; Oda, N; Takata, H; Takeda, Y; Usukura, M; Yamagishi, M; Yamamoto, Y; Yoneda, T | 1 |
| Böger, RH; Galle, J; Pinnetti, S; Schwedhelm, E; Wanner, C | 1 |
| Allen, TJ; Cao, Z; Cooper, ME; Hulthen, UL; Youssef, S | 1 |
| Cooper, ME; Gibbs, NJ; Kelly, DJ; Skinner, SL; Wilkinson-Berka, JL | 1 |
| Cooper, ME; Cox, AJ; Gilbert, RE; Kelly, DJ; Tolcos, M; Wilkinson-Berka, JL | 1 |
| Lin, S; Wen, H | 1 |
| Dagistanli, FK; Erek, E; Kalender, B; Oztürk, M; Tunçdemir, M; Uysal, O; Yegenaga, I | 1 |
7 review(s) available for valsartan and Diabetic Nephropathies
| Article | Year |
|---|---|
Effects of valsartan combined with α-lipoic acid on renal function in patients with diabetic nephropathy: a systematic review and meta-analysis.
Topics: Antihypertensive Agents; Antioxidants; Diabetic Nephropathies; Drug Therapy, Combination; Humans; Kidney; Thioctic Acid; Valsartan | 2021 |
Newer Drugs to Reduce High Blood Pressure and Mitigate Hypertensive Target Organ Damage.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Combinations; Female; Heart Failure; Humans; Hypertension; Male; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2022 |
Reduction of proteinuria with angiotensin receptor blockers.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Biomarkers; Cardiovascular Diseases; Diabetic Nephropathies; Drug Therapy, Combination; Enalapril; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2008 |
[Recent advance in kidney and hypertension research].
Topics: Albuminuria; Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Agonists; Catheter Ablation; Cerebrovascular Circulation; Chronic Disease; Diabetic Nephropathies; Drug Therapy, Combination; Evidence-Based Medicine; Fumarates; Humans; Hypertension; Imidazoles; Kidney; Kidney Diseases; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2012 |
[Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy].
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diastole; Diuretics; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Irbesartan; Losartan; Meta-Analysis as Topic; Placebos; Prognosis; Randomized Controlled Trials as Topic; Sodium Chloride Symporter Inhibitors; Systole; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2003 |
[Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension].
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diabetic Nephropathies; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Tetrazoles; Thiophenes; Valine; Valsartan | 2004 |
Angiotensin type 1 receptor blockers in chronic kidney disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Chronic Disease; Clinical Trials as Topic; Diabetic Nephropathies; Humans; Kidney Diseases; Losartan; Tetrazoles; Valine; Valsartan | 2004 |
22 trial(s) available for valsartan and Diabetic Nephropathies
| Article | Year |
|---|---|
Curative Effects of Valsartan Alone or Combined with Alpha-lipoic Acid on Inflammatory Cytokines and Renal Function in Early-stage Diabetic Kidney Disease.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; China; Cytokines; Diabetic Nephropathies; Drug Therapy, Combination; Female; Humans; Kidney Function Tests; Male; Middle Aged; Thioctic Acid; Valsartan | 2019 |
Evaluation of the efficacy and safety of TWHF in diabetic nephropathy patients with overt proteinuria and normal eGFR.
Topics: Adult; Aged; Antihypertensive Agents; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Phytotherapy; Plant Extracts; Proteinuria; Renin-Angiotensin System; Treatment Outcome; Tripterygium; Valsartan | 2020 |
Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial.
Topics: Adult; Aged; Benzazepines; Biomarkers; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Female; Humans; Italy; Kidney Function Tests; Male; Middle Aged; Slovenia; Treatment Outcome; Valsartan | 2019 |
Treatment of diabetic nephropathy with Tripterygium wilfordii Hook F extract: a prospective, randomized, controlled clinical trial.
Topics: Adult; Aged; Diabetic Nephropathies; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Male; Middle Aged; Phytotherapy; Plant Extracts; Prospective Studies; Tetrazoles; Treatment Outcome; Tripterygium; Valine; Valsartan | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diuretics; Female; Glucuronidase; Hospitals, University; Humans; Hydrochlorothiazide; Hypertension; Klotho Proteins; London; Male; Middle Aged; Phosphates; Pulse Wave Analysis; Renin-Angiotensin System; Systole; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2013 |
[Treatment of stage 3b diabetic kidney disease patients with macroalbuminuria by qizhi jiangtang capsule: a multicenter randomized control clinical study].
Topics: Adult; Albumins; Albuminuria; Blood Pressure; Creatinine; Diabetic Nephropathies; Drugs, Chinese Herbal; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2014 |
Assessment of glomerular filtration rate based on alterations of serum brain-derived neurotrophic factor in type 2 diabetic subjects treated with amlodipine/benazepril or valsartan/hydrochlorothiazide.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Brain-Derived Neurotrophic Factor; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Humans; Hydrochlorothiazide; Male; Middle Aged; Valsartan | 2015 |
Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Asian People; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Telmisartan; Tetrazoles; Valine; Valsartan | 2009 |
Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation.
Topics: Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; C-Reactive Protein; Calcium Channel Blockers; Chi-Square Distribution; Cytokine TWEAK; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Renin-Angiotensin System; Serum Amyloid P-Component; Tetrazoles; Time Factors; Treatment Outcome; Tumor Necrosis Factors; Turkey; Valine; Valsartan; Vasodilation | 2010 |
Is the reno-protective effect of valsartan dose dependent? A comparative study of 80 and 160 mg day(-1).
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; beta 2-Microglobulin; Blood Pressure; Blood Urea Nitrogen; Collagen Type IV; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypertension; Kidney; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2010 |
Evaluation of dosing time-related anti-hypertensive efficacy of valsartan in patients with type 2 diabetes.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2011 |
[The Shiga Microalbuminuria Reduction Trial].
Topics: Albuminuria; Amlodipine; Animals; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Middle Aged; Prospective Studies; Rats; Tetrazoles; Valine; Valsartan | 2010 |
Angiotensin II receptor blockade reduces salt sensitivity of blood pressure through restoration of renal nitric oxide synthesis in patients with diabetic nephropathy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Albuminuria; Angiotensin Receptor Antagonists; Biopterins; Blood Pressure; Deoxyguanosine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Hemodynamics; Humans; Kidney; Male; Middle Aged; Nitrates; Nitric Oxide; Nitrites; Receptors, Angiotensin; Sodium Chloride, Dietary; Tetrazoles; Valine; Valsartan | 2013 |
Renoprotective effects of low-dose valsartan in type 2 diabetic patients with diabetic nephropathy.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Blood Pressure; Body Mass Index; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2002 |
Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect.
Topics: Adult; Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2002 |
Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
Topics: Adult; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Double-Blind Method; Drug Synergism; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2003 |
Impact of renin angiotensin system blockade on night to day blood pressure ratio in diabetic nephropathy.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Blood Pressure; Circadian Rhythm; Diabetic Nephropathies; Humans; Renin-Angiotensin System; Risk Factors; Tetrazoles; Time Factors; Valine; Valsartan | 2006 |
Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Diabetic Nephropathies; Female; Humans; Hypertension; Male; Middle Aged; Oxidative Stress; Single-Blind Method; Tetrazoles; Trichlormethiazide; Valine; Valsartan | 2006 |
Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cardiovascular Diseases; Colorado; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Disease Progression; Female; Follow-Up Studies; Humans; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2006 |
Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Calcium Channel Blockers; Diabetic Nephropathies; Drug Therapy, Combination; Humans; Hypertension; Kidney; Middle Aged; Tetrazoles; Valine; Valsartan | 2007 |
Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus.
Topics: Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Female; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2007 |
Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Arginine; Benzimidazoles; Benzoates; Blood Pressure; C-Reactive Protein; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dinoprost; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Proteinuria; Renin-Angiotensin System; Telmisartan; Tetrazoles; Valine; Valsartan | 2008 |
52 other study(ies) available for valsartan and Diabetic Nephropathies
| Article | Year |
|---|---|
Effects of calcium dobesilate combined with categlicine and valsartan capsules on inflammation and cellular immunity in patients with diabetic nephropathy.
Topics: Calcium Dobesilate; Capsules; Diabetes Mellitus; Diabetic Nephropathies; Humans; Immunity, Cellular; Inflammation; Valsartan | 2023 |
Effects of Valsartan on LN, FN, MDA, Renal Tissue Fibrosis, and Inflammatory Infiltration in DN Rats.
Topics: Animals; Diabetic Nephropathies; Fibronectins; Fibrosis; Laminin; Male; Rats; Valsartan | 2022 |
Yi-Shen-Hua-Shi granule ameliorates diabetic kidney disease by the "gut-kidney axis".
Topics: Animals; Blood Glucose; Chromatography, Liquid; Diabetes Mellitus; Diabetic Nephropathies; Glucose; Glycerophospholipids; Herbal Medicine; Kidney; Rats; Saline Solution; Sphingolipids; Tandem Mass Spectrometry; Tryptophan; Valsartan | 2023 |
Effects of Valsartan and Amlodipine Tablets Combined with α-Lipoic Acid on T-AOC, IL-6 and β2-MG Levels in Patients with Diabetic Nephropathy.
Topics: Amlodipine; Antihypertensive Agents; Antioxidants; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hypertension; Interleukin-6; Tablets; Thioctic Acid; Valsartan | 2023 |
Sacubitril/valsartan ameliorates renal tubulointerstitial injury through increasing renal plasma flow in a mouse model of type 2 diabetes with aldosterone excess.
Topics: Aldosterone; Animals; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fibrosis; Kidney; Male; Mice; Natriuretic Peptides; Renal Plasma Flow; Valsartan | 2023 |
[Effect of multi-glycosides of Tripterygium wilfordii on renal injury in diabetic kidney disease rats through NLRP3/caspase-1/GSDMD pyroptosis pathway].
Topics: Animals; Caspase 1; Diabetes Mellitus; Diabetic Nephropathies; Glycosides; Interleukin-18; Kidney; Male; NLR Family, Pyrin Domain-Containing 3 Protein; Pyroptosis; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tripterygium; Uridine Triphosphate; Valsartan | 2023 |
Therapeutic improvements of nifedipine controlled-release tablets combined with sacubitril valsartan on patients with diabetic nephropathy complicated with hypertension.
Topics: Biphenyl Compounds; Delayed-Action Preparations; Diabetes Mellitus; Diabetic Nephropathies; Drug Combinations; Humans; Hypertension; Nifedipine; Tetrazoles; Valsartan | 2023 |
Angiopoietin-like protein 3 deficiency combined with valsartan administration protects better against podocyte damage in streptozotocin-induced diabetic nephropathy mice.
Topics: Angiopoietin-Like Protein 3; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Kidney Failure, Chronic; Mice; Podocytes; Reactive Oxygen Species; Streptozocin; Valsartan | 2023 |
Silibinin Augments the Antifibrotic Effect of Valsartan Through Inactivation of TGF-β1 Signaling in Kidney.
Topics: Animals; Cell Line; Diabetic Nephropathies; Disease Models, Animal; Drug Synergism; Epithelial-Mesenchymal Transition; Fibrosis; Humans; Kidney Tubules, Proximal; Male; Mice; Mice, Inbred C57BL; Renal Insufficiency, Chronic; Signal Transduction; Silybin; Transforming Growth Factor beta1; Valsartan | 2020 |
Up-regulation of matrix metalloproteinases-9 in the kidneys of diabetic rats and the association with neutrophil gelatinase-associated lipocalin.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Kidney Tubules, Proximal; Lipocalin-2; Male; Matrix Metalloproteinase 9; Random Allocation; Rats; Rats, Sprague-Dawley; Up-Regulation; Valsartan | 2021 |
Blocking angiotensin 2 receptor attenuates diabetic nephropathy via mitigating ANGPTL2/TL4/NF-κB expression.
Topics: Angiopoietin-Like Protein 2; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Gene Expression; Kidney; Male; NF-kappa B; Protective Agents; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Receptor, Angiotensin, Type 2; RNA, Messenger; Streptozocin; Toll-Like Receptor 4; Treatment Outcome; Valsartan | 2021 |
Advanced glycation end products induce the apoptosis of and inflammation in mouse podocytes through CXCL9-mediated JAK2/STAT3 pathway activation.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cell Line; Chemokine CXCL9; Diabetic Nephropathies; Gene Expression Regulation; Glycation End Products, Advanced; Humans; Interleukin-6; Intracellular Signaling Peptides and Proteins; Janus Kinase 2; Membrane Proteins; Mice; Podocytes; Proto-Oncogene Proteins c-bcl-2; Receptors, Angiotensin; Receptors, CXCR3; RNA, Small Interfering; Signal Transduction; STAT3 Transcription Factor; Tumor Necrosis Factor-alpha; Tyrphostins; Valsartan | 2017 |
Angiotensin II receptor blocker valsartan ameliorates cardiac fibrosis partly by inhibiting miR-21 expression in diabetic nephropathy mice.
Topics: Angiotensin Receptor Antagonists; Animals; Base Sequence; Biomarkers; Diabetic Nephropathies; Extracellular Matrix Proteins; Fibrosis; Gene Expression Regulation; Matrix Metalloproteinase 9; Mice, Inbred C57BL; MicroRNAs; Myocardium; Valsartan | 2018 |
FPS-ZM1 and valsartan combination protects better against glomerular filtration barrier damage in streptozotocin-induced diabetic rats.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Benzamides; Biomarkers; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug Therapy, Combination; Glomerular Filtration Barrier; Injections, Intraperitoneal; Macrophages; Male; Microscopy, Fluorescence; Phosphorylation; Podocytes; Protein Processing, Post-Translational; Random Allocation; Rats, Wistar; Receptor for Advanced Glycation End Products; Renal Insufficiency; Transcription Factor RelA; Valsartan | 2018 |
The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Arterial Pressure; Biomarkers; Biphenyl Compounds; Blood Glucose; Diabetic Nephropathies; Disease Models, Animal; Drug Combinations; Fibrosis; Kidney Glomerulus; Kidney Tubules; Lipids; Male; Neprilysin; Nitrosative Stress; Oxidative Stress; Protease Inhibitors; Proteinuria; Rats, Zucker; Tetrazoles; Time Factors; Valsartan | 2019 |
Angiotensin blockade attenuates diabetic nephropathy in hypogonadal adult male rats.
Topics: Angiotensin II; Angiotensins; Animals; Collagen Type IV; Diabetic Nephropathies; Estradiol; Follicle Stimulating Hormone; Glycated Hemoglobin; Hypogonadism; Kidney; Letrozole; Luteinizing Hormone; Male; NF-kappa B; Organ Size; Oxidative Stress; Rats; Signal Transduction; Testosterone; Transforming Growth Factor beta1; Valsartan | 2019 |
Angiotensin-converting enzyme inhibition and angiotensin AT1 receptor blockade downregulate angiotensin-converting enzyme expression and attenuate renal injury in streptozotocin-induced diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enalapril; Gene Expression Regulation, Enzymologic; Kidney; Male; Peptidyl-Dipeptidase A; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan | 2013 |
Valsartan slows the progression of diabetic nephropathy in db/db mice via a reduction in podocyte injury, and renal oxidative stress and inflammation.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Progression; Extracellular Matrix Proteins; Fibronectins; Gene Expression Regulation; Inflammation; Intracellular Signaling Peptides and Proteins; Kidney; Kidney Cortex; Kidney Glomerulus; Membrane Proteins; Mice; Oxidative Stress; Plasminogen Activator Inhibitor 1; Podocytes; RNA, Messenger; Tetrazoles; Transforming Growth Factor beta1; Treatment Outcome; Valine; Valsartan; WT1 Proteins | 2014 |
Protective effects of aliskiren and valsartan in mice with diabetic nephropathy.
Topics: Albumins; Amides; Animals; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endoplasmic Reticulum Stress; Fumarates; Inflammation; Lipid Metabolism; Male; Membrane Proteins; Mesangial Cells; Mice, Inbred DBA; Podocytes; Protective Agents; Proteinuria; Proto-Oncogene Mas; Proto-Oncogene Proteins; Receptors, G-Protein-Coupled; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2014 |
Angiotensin(1-7) attenuates the progression of streptozotocin-induced diabetic renal injury better than angiotensin receptor blockade.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Proliferation; Collagen Type IV; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Progression; Male; Mesangial Cells; Oxidative Stress; Peptide Fragments; Proto-Oncogene Mas; Proto-Oncogene Proteins; Rats; Rats, Wistar; Receptors, G-Protein-Coupled; Signal Transduction; Smad3 Protein; Transforming Growth Factor beta1; Valsartan; Vascular Endothelial Growth Factor A | 2015 |
Clinical study of double dose of valsartan combined with tacrolimus in treatment of diabetic nephropathy.
Topics: Adult; Aged; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Renal Agents; Tacrolimus; Valsartan | 2016 |
Blood pressure-independent renoprotection in diabetic rats treated with AT1 receptor-neprilysin inhibition compared with AT1 receptor blockade alone.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Natriuretic Factor; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug Combinations; Neprilysin; Rats; Rats, Sprague-Dawley; Streptozocin; Tetrazoles; Valsartan | 2016 |
The association of ACE gene polymorphism with diabetic kidney disease and renoprotective efficacy of valsartan.
Topics: Diabetic Nephropathies; Female; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Peptidyl-Dipeptidase A; Protective Agents; Valsartan | 2016 |
[Effects of valsartan, mycophenolate mofetil and their combined application on TRAIL and nuclear factor-kappaB expression in the kidneys of diabetic rats].
Topics: Animals; Antihypertensive Agents; Apoptosis; Apoptosis Regulatory Proteins; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Drug Therapy, Combination; Immunosuppressive Agents; Kidney; Male; Mycophenolic Acid; NF-kappa B; Random Allocation; Rats; Rats, Wistar; Tetrazoles; TNF-Related Apoptosis-Inducing Ligand; Treatment Outcome; Valine; Valsartan | 2008 |
Regulation of renal 12(S)-hydroxyeicosatetraenoic acid in diabetes by angiotensin AT1 and AT2 receptors.
Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hypoglycemic Agents; Imidazoles; In Vitro Techniques; Insulin; Kidney; Male; Microdialysis; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan | 2008 |
Very high doses of valsartan provide renoprotection independently of blood pressure in a type 2 diabetic nephropathy rat model.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Hypertension; Linear Models; Male; Proteinuria; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrazoles; Valine; Valsartan | 2009 |
Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice.
Topics: Albuminuria; Amides; Animals; Collagen Type IV; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Synergism; Fumarates; Kidney Glomerulus; Losartan; Male; Mice; Mice, Inbred C57BL; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2010 |
Local delivery of angiotensin II receptor blockers into the kidney passively attenuates inflammatory reactions during the early phases of streptozotocin-induced diabetic nephropathy through inhibition of calpain activity.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Calpain; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Inflammation; Kidney Glomerulus; Male; NF-kappa B; Nitric Oxide Synthase Type III; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Streptozocin; Tetrazoles; Transcription Factor RelA; Valine; Valsartan | 2010 |
Treatment of db/db diabetic mice with triptolide: a novel therapy for diabetic nephropathy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Body Weight; Chemokine CCL2; Desmin; Diabetic Nephropathies; Diterpenes; Epoxy Compounds; Glomerular Filtration Rate; Immunohistochemistry; Kidney; Lipids; Liver; Mice; Mice, Inbred C57BL; Microscopy, Electron; Phenanthrenes; Podocytes; Reactive Oxygen Species; T-Lymphocytes; Tetrazoles; Valine; Valsartan | 2010 |
Renal (pro)renin receptor contributes to development of diabetic kidney disease through transforming growth factor-β1-connective tissue growth factor signalling cascade.
Topics: Animals; Connective Tissue Growth Factor; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glucose; Hyperglycemia; Male; Mesangial Cells; Oligopeptides; Prorenin Receptor; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptors, Cell Surface; RNA, Small Interfering; Signal Transduction; Tetrazoles; Transforming Growth Factor beta1; Up-Regulation; Valine; Valsartan | 2011 |
Effects of multiple factorial intervention on ambulatory BP profile and renal function in hypertensive type 2 diabetic patients with overt nephropathy - a pilot study.
Topics: Albuminuria; Anticholesteremic Agents; Antihypertensive Agents; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fatty Acids, Monounsaturated; Female; Fluvastatin; Glomerular Filtration Rate; Heart Rate; Humans; Hypertension; Indoles; Kidney; Lipids; Male; Middle Aged; Pilot Projects; Prospective Studies; Regression Analysis; Tetrazoles; Valine; Valsartan | 2011 |
Valsartan attenuated oxidative stress, decreased MCP-1 and TGF-β1 expression in glomerular mesangial and epithelial cells induced by high-glucose levels.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cell Culture Techniques; Cells, Cultured; Chemokine CCL2; Culture Media; Diabetic Nephropathies; Epithelial Cells; Glucose; Glutathione; Malondialdehyde; Mesangial Cells; Oxidative Stress; Rats; Reactive Oxygen Species; Superoxide Dismutase; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan | 2011 |
Valsartan inhibited HIF-1α pathway and attenuated renal interstitial fibrosis in streptozotocin-diabetic rats.
Topics: Animals; Blood Glucose; Blotting, Western; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endothelin-1; Gene Expression; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Kidney; Male; Nephritis, Interstitial; Proteinuria; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Streptozocin; Tetrazoles; Tissue Inhibitor of Metalloproteinase-1; Valine; Valsartan | 2012 |
Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biomarkers; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dihydropyridines; Disease Progression; Drug Therapy, Combination; Glomerulonephritis; Glucagon; Glucose Transporter Type 1; Glycated Hemoglobin; Glycogen; Hypertension; Kidney; Male; Norepinephrine; Proteinuria; Rats; Rats, Inbred SHR; Renin-Angiotensin System; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan | 2013 |
Clinical evaluation of valsartan and metoprolol tartrate in treatment of diabetic nephropathy with positive β1-adrenergic and anti-angiotensin II type 1 receptor antibody.
Topics: Aged; Autoantibodies; Diabetic Nephropathies; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Metoprolol; Receptor, Angiotensin, Type 1; Receptors, Adrenergic, beta-1; Tetrazoles; Valine; Valsartan | 2012 |
Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin.
Topics: Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Drug Therapy, Combination; Hypertension; Kidney Glomerulus; Male; Membrane Proteins; Proteins; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Sclerosis; Systole; Tetrazoles; Valine; Valsartan; Verapamil | 2003 |
The angiotensin II type 1 receptor mediates renal interstitial content of tumor necrosis factor-alpha in diabetic rats.
Topics: Albuminuria; Animals; Antihypertensive Agents; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Extracellular Space; Hypertension, Renal; Kidney; Male; Microdialysis; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2003 |
Renal nitric oxide production is decreased in diabetic rats and improved by AT1 receptor blockade.
Topics: Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Extracellular Fluid; Kidney; Losartan; Nitric Oxide; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan | 2004 |
[Type 2 diabetic patient with kidney damage. Sartans banish dialysis risk].
Topics: Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Kidney Failure, Chronic; Randomized Controlled Trials as Topic; Renal Dialysis; Tetrazoles; Valine; Valsartan | 2004 |
How FDA currently makes decisions on clinical studies.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Carbazoles; Carvedilol; Child; Clinical Trials as Topic; Diabetic Nephropathies; Evidence-Based Medicine; Heart Failure; Humans; Propanolamines; Tetrazoles; United States; United States Food and Drug Administration; Valine; Valsartan | 2005 |
[Hypertension and diabetic nephropathy, a dangerous duo].
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diuretics; Drug Therapy, Combination; Enalapril; Glomerular Filtration Rate; Humans; Hypertension; Male; Metabolic Syndrome; Ramipril; Tetrazoles; Valine; Valsartan | 2005 |
ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arginine; Benzimidazoles; Benzoates; Clinical Protocols; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dinoprost; Endothelium, Vascular; Humans; Hypertension; Middle Aged; Multicenter Studies as Topic; Oxidative Stress; Randomized Controlled Trials as Topic; Renal Insufficiency; Telmisartan; Tetrazoles; Valine; Valsartan | 2005 |
Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Collagen Type IV; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Drug Therapy, Combination; Enalapril; Female; Glycation End Products, Advanced; Mice; Mice, Inbred C57BL; Mice, Obese; Pyridoxamine; Tetrazoles; Valine; Valsartan; Vitamin B Complex | 2006 |
[Valsartan: arguments for the high dose concept].
Topics: Angiotensin II Type 1 Receptor Blockers; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Humans; Hypertension, Renal; Proteinuria; Tetrazoles; Valine; Valsartan | 2006 |
Effects of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy in rats.
Topics: Animals; Chemokine CCL2; Desmin; Diabetic Nephropathies; Drug Therapy, Combination; Immunohistochemistry; Male; Membrane Proteins; Mycophenolic Acid; Podocytes; Rats; Rats, Wistar; Tetrazoles; Valine; Valsartan | 2007 |
[New effective dosage of valsartan. High dosage--effective against high blood pressure].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetic Nephropathies; Dose-Response Relationship, Drug; Heart Failure; Humans; Hypertension; Prognosis; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2007 |
[Risk oriented therapy of hypertension. Lowering blood pressure and risk].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetic Nephropathies; Humans; Hypertension; Randomized Controlled Trials as Topic; Risk Factors; Tetrazoles; Valine; Valsartan | 2007 |
Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies.
Topics: Albuminuria; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Bradykinin; Bradykinin Receptor Antagonists; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Kidney; Kidney Glomerulus; Male; Organ Size; Ramipril; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 1997 |
Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)27 rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Progression; Drug Therapy, Combination; Female; Heterozygote; Kidney; Perindopril; Rats; Renin; Tetrazoles; Valine; Valsartan | 2001 |
Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Antihypertensive Agents; Apoptosis; Atrophy; Autoradiography; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Epidermal Growth Factor; Female; Fibrosis; Gene Expression; In Situ Hybridization; In Situ Nick-End Labeling; Kidney Tubules; Nephritis, Interstitial; Perindopril; Rats; Renin-Angiotensin System; RNA, Messenger; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2002 |
[Renal protective effect of valsartan in diabetic rats].
Topics: Animals; Collagen Type IV; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Down-Regulation; Fibronectins; Kidney; Male; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tetrazoles; Transforming Growth Factor beta; Transforming Growth Factor beta1; Valine; Valsartan | 1999 |
Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in rats.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enalapril; Female; Immunoenzyme Techniques; Immunohistochemistry; Kidney; Organ Size; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2002 |